Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741715 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,736
- Enrollment target
NCT00741715 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 1,736 participants.
The verdict
NCT00741715, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,736 participants
- Enrollment target
Study Summary
The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of the association AVE5530+atorvastatin on LDL-C level reduction after 12 weeks of treatment. The effects of AVE5530+atorvastatin on other lipid parameters will be assessed as secondary objectives
Interventions
- DRUG placebo
- DRUG atorvastatin
- DRUG AVE5530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,736 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741715
The ClinicalTrials.gov registry entry for NCT00741715 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,736 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00741715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741715 about?
NCT00741715 is a clinical study titled "Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia". The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary hypercholesterolemia. The main objectiv...
What is the current status of trial NCT00741715?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,736 participants. The study started on 2008-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00741715?
The interventions under investigation include: placebo (DRUG), atorvastatin (DRUG), AVE5530 (DRUG).
Who is sponsoring clinical trial NCT00741715?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.